Financials

v2.4.1.9
Consolidated Balance Sheets (Unaudited) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 4,256,016us-gaap_CashAndCashEquivalentsAtCarryingValue $ 3,103,969us-gaap_CashAndCashEquivalentsAtCarryingValue
Short-term investments 769,700us-gaap_ShortTermInvestments  
Accounts receivable 307,404us-gaap_AccountsReceivableNetCurrent 267,199us-gaap_AccountsReceivableNetCurrent
Other current assets 248,616us-gaap_OtherAssetsCurrent 174,179us-gaap_OtherAssetsCurrent
Total current assets 5,581,736us-gaap_AssetsCurrent 3,545,347us-gaap_AssetsCurrent
Equipment, net 209,641us-gaap_PropertyPlantAndEquipmentNet 244,537us-gaap_PropertyPlantAndEquipmentNet
Restricted cash 815,883us-gaap_RestrictedCashAndCashEquivalentsNoncurrent 1,699,759us-gaap_RestrictedCashAndCashEquivalentsNoncurrent
Other long-term assets 48,961us-gaap_OtherAssetsNoncurrent 56,131us-gaap_OtherAssetsNoncurrent
Investment in Incuron, LLC 4,020,892us-gaap_EquityMethodInvestments 4,268,458us-gaap_EquityMethodInvestments
Total assets 10,677,113us-gaap_Assets 9,814,232us-gaap_Assets
Current liabilities:    
Accounts payable 989,646us-gaap_AccountsPayableCurrent 1,057,743us-gaap_AccountsPayableCurrent
Accrued expenses 2,070,984us-gaap_AccruedLiabilitiesCurrent 1,804,456us-gaap_AccruedLiabilitiesCurrent
Deferred revenue 418,673us-gaap_DeferredRevenueCurrent 156,317us-gaap_DeferredRevenueCurrent
Accrued warrant liability 4,547,691us-gaap_DerivativeLiabilitiesCurrent 862,074us-gaap_DerivativeLiabilitiesCurrent
Current portion of notes payable 2,736,365us-gaap_NotesPayableCurrent 2,640,968us-gaap_NotesPayableCurrent
Current portion of capital lease obligation   7,522us-gaap_CapitalLeaseObligationsCurrent
Total current liabilities 10,763,359us-gaap_LiabilitiesCurrent 6,529,080us-gaap_LiabilitiesCurrent
Long-term debt 1,321,218us-gaap_LongTermDebt 1,499,050us-gaap_LongTermDebt
Commitments and contingencies      
Total liabilities 12,084,577us-gaap_Liabilities 8,028,130us-gaap_Liabilities
Stockholders' equity:    
Preferred stock, $.005 par value; 10,000,000 shares authorized, 717.4 and 0 shares issued and outstanding as of March 31, 2015 and 2014, respectively 0us-gaap_PreferredStockValue 0us-gaap_PreferredStockValue
Common stock, $.005 par value; 160,000,000 shares authorized, 3,435,354 and 2,547,140 shares issued and outstanding as of March 31, 2015 and 2014, respectively 17,173us-gaap_CommonStockValue 14,287us-gaap_CommonStockValue
Additional paid-in capital 133,235,836us-gaap_AdditionalPaidInCapital 132,693,988us-gaap_AdditionalPaidInCapital
Other comprehensive income/(loss) (450,172)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax (380,110)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Accumulated deficit (138,261,859)us-gaap_RetainedEarningsAccumulatedDeficit (133,935,562)us-gaap_RetainedEarningsAccumulatedDeficit
Total Cleveland BioLabs, Inc. stockholders' equity (deficit) (5,459,022)us-gaap_StockholdersEquity (1,607,397)us-gaap_StockholdersEquity
Noncontrolling interest in stockholders' equity 4,051,554us-gaap_MinorityInterest 3,393,499us-gaap_MinorityInterest
Total stockholders' equity (1,407,468)us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 1,786,102us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Total liabilities and stockholders' equity 10,677,113us-gaap_LiabilitiesAndStockholdersEquity 9,814,232us-gaap_LiabilitiesAndStockholdersEquity
Convertible Preferred Stock [Member]    
Current liabilities:    
Convertible Preferred Stock, $.005 par value, 718 shares designated, 717.4 shares issued and outstanding $ 4us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
/ us-gaap_StatementClassOfStockAxis
= us-gaap_ConvertiblePreferredStockMember
 
v2.4.1.9
Consolidated Statements of Operations (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Revenues:    
Grants and contracts $ 607,329us-gaap_ContractsRevenue $ 1,334,254us-gaap_ContractsRevenue
Operating expenses:    
Research and development 1,610,970us-gaap_ResearchAndDevelopmentExpense 2,439,773us-gaap_ResearchAndDevelopmentExpense
General and administrative 2,307,871us-gaap_GeneralAndAdministrativeExpense 2,413,543us-gaap_GeneralAndAdministrativeExpense
Total operating expenses 3,918,841us-gaap_OperatingExpenses 4,853,316us-gaap_OperatingExpenses
Loss from operations (3,311,512)us-gaap_OperatingIncomeLoss (3,519,062)us-gaap_OperatingIncomeLoss
Other income (expense):    
Interest and other expense (46,394)us-gaap_OtherNonoperatingIncomeExpense (317,922)us-gaap_OtherNonoperatingIncomeExpense
Foreign exchange loss (43,735)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax (151,771)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax
Change in value of warrant liability (49,358)us-gaap_FairValueAdjustmentOfWarrants 2,087,558us-gaap_FairValueAdjustmentOfWarrants
Equity in loss of Incuron, LLC (247,566)us-gaap_IncomeLossFromEquityMethodInvestments  
Total other income (387,053)us-gaap_NonoperatingIncomeExpense 1,617,865us-gaap_NonoperatingIncomeExpense
Net loss (3,698,565)us-gaap_ProfitLoss (1,901,197)us-gaap_ProfitLoss
Net loss attributable to noncontrolling interests 48,243us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 315,825us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net loss attributable to Cleveland BioLabs, Inc. $ (3,650,322)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,585,372)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Net loss available to common stockholders per share of common stock, basic and diluted $ (1.14)us-gaap_EarningsPerShareBasicAndDiluted $ (0.63)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average number of shares used in calculating net loss per share, basic and diluted 3,206,249us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 2,498,407us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
v2.4.1.9
Consolidated Statements of Cash Flows (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Cash flows from operating activities:    
Net income (loss) $ (3,698,565)us-gaap_ProfitLoss $ (1,901,197)us-gaap_ProfitLoss
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation 38,620us-gaap_Depreciation 57,811us-gaap_Depreciation
Amortization of loan costs 27,019us-gaap_AdjustmentForAmortization 91,929us-gaap_AdjustmentForAmortization
(Gain) loss on equipment disposal   24,685us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Noncash compensation 33,640us-gaap_AllocatedShareBasedCompensationExpense 48,416us-gaap_AllocatedShareBasedCompensationExpense
Warrant issuance costs 617,776cbli_WarrantIssuanceCosts 171,116cbli_WarrantIssuanceCosts
Equity in loss of Incuron, LLC 247,566us-gaap_IncomeLossFromEquityMethodInvestments  
Change in value of warrant liability 49,358us-gaap_FairValueAdjustmentOfWarrants (2,087,558)us-gaap_FairValueAdjustmentOfWarrants
Changes in operating assets and liabilities:    
Accounts receivable (39,959)us-gaap_IncreaseDecreaseInAccountsReceivable 41,901us-gaap_IncreaseDecreaseInAccountsReceivable
Other current assets (73,276)us-gaap_IncreaseDecreaseInOtherCurrentAssets (54,818)us-gaap_IncreaseDecreaseInOtherCurrentAssets
Other long-term assets 3,986us-gaap_IncreaseDecreaseInOtherNoncurrentAssets 9,847us-gaap_IncreaseDecreaseInOtherNoncurrentAssets
Accounts payable (57,910)us-gaap_IncreaseDecreaseInAccountsPayable (273,086)us-gaap_IncreaseDecreaseInAccountsPayable
Deferred revenue 254,363us-gaap_IncreaseDecreaseInDeferredRevenue 108,127us-gaap_IncreaseDecreaseInDeferredRevenue
Accrued expenses 369,832us-gaap_IncreaseDecreaseInAccruedLiabilities 929,518us-gaap_IncreaseDecreaseInAccruedLiabilities
Net cash used in operating activities (2,227,550)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (2,833,309)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:    
Purchase of short-term investments (723,661)us-gaap_PaymentsToAcquireHeldToMaturitySecurities  
Purchase of equipment (3,756)us-gaap_PaymentsToAcquireMachineryAndEquipment (10,805)us-gaap_PaymentsToAcquireMachineryAndEquipment
Decrease in restricted cash 770,609us-gaap_DecreaseInRestrictedCash  
Net cash provided by (used in) investing activities 43,192us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (10,805)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:    
Issuance of common stock, net of offering costs 3,501,457us-gaap_ProceedsFromIssuanceOfCommonStock 6,355,001us-gaap_ProceedsFromIssuanceOfCommonStock
Net proceeds/(repayment) of long-term debt (182,058)us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities  
Repayment of capital lease obligation (7,522)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations (19,806)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations
Net cash provided by financing activities 3,311,877us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 6,335,195us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Effect of exchange rate change on cash and equivalents 24,528us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents (147,850)us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents
Decrease in cash and cash equivalents 1,152,047us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 3,343,231us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of period 3,103,969us-gaap_CashAndCashEquivalentsAtCarryingValue 10,048,466us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of period 4,256,016us-gaap_CashAndCashEquivalentsAtCarryingValue 13,391,697us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 47,782us-gaap_InterestPaid 159,780us-gaap_InterestPaid
Supplemental schedule of noncash financing activities:    
Noncash financing costs on common stock offering   50,505cbli_NoncashFinancingCostsOnCommonStockOffering
Noncash warrant issuance costs   $ 15,993cbli_NoncashWarrantIssuanceCostsOnCommonStockOffering
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue